HNO Donor

Bristol-Myers Squibb · Phase 2 active Small molecule

At a glance

Generic name	HNO Donor
Also known as	BMS-986231
Sponsor	Bristol-Myers Squibb
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure (PHASE2)
A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HNO Donor CI brief — competitive landscape report
HNO Donor updates RSS · CI watch RSS
Bristol-Myers Squibb portfolio CI